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ARTICLE
The splicing factor RBM25 controls MYC activity in
acute myeloid leukemia
Ying Ge1,2,3, Mikkel Bruhn Schuster1,2,3, Sachin Pundhir1,2,3,4, Nicolas Rapin1,2,3,4, Frederik Otzen Bagger1,2,3,4,
Nikos Sidiropoulos1, Nadia Hashem1,2,3 & Bo Torben Porse 1,2,3
Cancer sequencing studies have implicated regulators of pre-mRNA splicing as important
disease determinants in acute myeloid leukemia (AML), but the underlying mechanisms have
remained elusive. We hypothesized that “non-mutated” splicing regulators may also play a
role in AML biology and therefore conducted an in vivo shRNA screen in a mouse model of
CEBPA mutant AML. This has led to the identiﬁcation of the splicing regulator RBM25 as a
novel tumor suppressor. In multiple human leukemic cell lines, knockdown of RBM25 pro-
motes proliferation and decreases apoptosis. Mechanistically, we show that RBM25 controls
the splicing of key genes, including those encoding the apoptotic regulator BCL-X and the
MYC inhibitor BIN1. This mechanism is also operative in human AML patients where low
RBM25 levels are associated with high MYC activity and poor outcome. Thus, we demon-
strate that RBM25 acts as a regulator of MYC activity and sensitizes cells to increased MYC
levels.
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Acute myeloid leukemia (AML) is an aggressive hemato-logical disorder for which there is an unmet medical needfor novel treatment strategies. AML constitutes an arres-
ted state of development in which leukemic blasts, resembling
normal myeloid progenitor cells, fail to terminally differentiate
and consequently accumulate in the bone marrow (BM) and
peripheral organs. In addition, seminal work has demonstrated
that AML is maintained by relatively rare populations of leukemic
stem cells (LSCs) with self-renewal capacity1,2. Thus insights into
how these cells are controlled hold the potential of serving as a
starting point for the rational development of novel treatment
strategies.
Recent cancer genome sequencing studies have revealed the
genetics of many cancers including AML. In addition to genes
encoding epigenetic regulators, transcription factors, and growth
regulators, splicing factor genes are often mutated in human
AML3. Recurrently mutated splicing factors in AML include
SRSF2, SF3B1, and U2AF1 and these lesions are found in
approximately 10% of patients4,5. The latter factors are involved
in pre-mRNA splicing, a process catalyzed by the spliceosome—a
major ribonucleoprotein complex that acts in a sequential man-
ner to remove introns6. In addition to core spliceosome compo-
nents, splicing is also inﬂuenced by a set of regulatory factors that
promote or repress deﬁned steps during the process in a pre-
mRNA-speciﬁc manner resulting in a range of so-called alter-
natively spliced transcripts7,8. These transcripts may have an
impact on downstream protein production via different means.
Commonly, alternative splicing affects transcript stability, i.e.
leads to changes in protein levels, but may also affect coding
potential leading to the expression of proteins with distinct
functional properties.
Despite the fact that splicing factor mutations are commonly
found in AML and other hematological malignances, including
myelodysplastic syndrome (MDS), it has remained largely elusive
how they mediate or sustain oncogenic transformation9. Gen-
erally, mutations of these factors inﬂuence the splicing patterns of
hundreds of pre-mRNAs and whether this malignant phenotype
is driven by individual variants (and if so which) or the sum of
changes has proven difﬁcult to resolve10. Moreover, the ﬁnding
that splicing patterns are also affected in AML patient samples
with no obvious mutations in splicing-related genes suggests that
splicing regulators may be affected by other means including
epigenetically induced de-regulation11.
Loss-of-function (LOF) screens using siRNA, shRNA, or
CRISPR-based approaches have been used extensively for the
identiﬁcation of oncogenes and tumor suppressors. LOF screens
are generally performed in vitro, not least due to the excellent
library coverage that can be obtained in a controlled experimental
setting with nearly unlimited amounts of cells. However, in vitro
screens may miss genes that are important only in an in vivo
setting or detect genes that are important only in an in vitro
setting. Hence ideally, LOF screens should be performed
in vivo in relevant model systems12. CEBPA is an important
myeloid transcription factor that is frequently mutated in human
AML, and biallelic CEBPA mutant AML constitutes a speciﬁc
AML subtype3,13,14. The underlying genetic lesions in biallelic
CEBPA mutant AML converge at the selective expression of the
p30 isoform, i.e. an N-terminally truncated version of CEBPA. In
contrast to full-length (p42) CEBPA, this variant is unable
to facilitate E2F-mediated cell cycle repression and it also targets a
slightly different set of promoters and enhancers15–17 (manu-
script in preparation). In mice, the exclusive expression of the p30
isoform from the endogenous Cebpa locus leads to the develop-
ment of AML within a year and this mouse line (Lp30) therefore
constitutes an excellent model for human biallelic CEBPA mutant
AML18.
Here we have conducted an in vivo shRNA screen in the
context of the Cebpa mutant AML mouse model aimed at iden-
tifying novel tumor suppressors and oncogenes among potential
splicing regulators. This led to the identiﬁcation of RBM25, a
relatively uncharacterized RNA binding protein, as a potential
tumor suppressor. Using a variety of human leukemic cell lines
and a hierarchical organized AML cell culture system, we
demonstrated that loss of RBM25 leads to a decrease of apoptosis
and an increase in the proliferation of not only bulk leukemic
cells, but also cells with LSC properties. Molecularly, we showed
that RBM25 controls the splicing of a number of key pre-mRNAs
including those encoding the apoptotic regulator BCL-X and the
MYC inhibitor, BIN1. Thus our ﬁndings provide not only novel
mechanistic insights into the role of RBM25 in AML but also a
proof-of-concept for the functional importance of splicing de-
regulation in AML biology in general.
Results
Identiﬁcation of novel splicing regulators in murine AML. In
order to identify splicing factors that functionally affect AML
biology, we conducted an in vivo pooled shRNA screen in the
Lp30 AML model. The screen was based on the assumption that
when AML cells are transduced with a mixture of shRNAs,
continuous proliferation of the cells will lead to the gradual
depletion of shRNAs targeting tumor-promoting genes and vice
versa for shRNAs targeting tumor suppressive genes.
To investigate the speciﬁc effects of factors involved in
posttranscriptional pre-mRNA processing, we constructed a
retroviral shRNA library containing 613 shRNAs targeting 230
known or putative splicing factor-encoding genes. The targets
include all major known and putative splicing associated gene
families, such as Serine/Arginine-rich proteins (SR proteins),
heterogeneous nuclear ribonucleoproteins (hnRNPs), and RNA
binding motif proteins (Fig. 1a and Supplementary Data 1). The
library was used to transduce AML cells derived from the Lp30
mice and these cells were subsequently transplanted into
secondary recipients. Following the development of secondary
AML, the shRNA repertoires of input and secondary AML cells
were determined by next-generation sequencing in order to
quantify changes in the representation of individual shRNAs
(Fig. 1b). Since we were mainly interested in targets speciﬁcally
affecting growth of leukemic cells, but not of their normal
hematopoietic counterparts, we also performed an in vitro
counter screen in normal c-Kit-enriched murine hematopoietic
progenitors (Supplementary Fig. 1a). We selected an shRNA pool
size of 150 based on a preliminary screen with increasing pool
sizes, followed by assessment of correlation between the replicates
(Supplementary Fig. 1b).
The in vivo AML screen was performed in duplicate and we
observed a near-complete coverage of the shRNA pools
(Supplementary Fig. 1c) as well as moderate correlation (R=
0.53) between the biological replicates when comparing the fold-
change (FC) in shRNA representation between start and endpoint
cells (Supplementary Fig. 1d). shRNAs were ranked based on
their mean FC (Fig. 1c), and a gene was scored as a hit if targeted
by multiple shRNAs ranked within the 20th percentile of the
most enriched or 25th percentile of the most depleted shRNAs in
Lp30 cells, but not in normal c-Kit+ cells. This resulted in the
identiﬁcation of six enriched and eight depleted candidate genes
(Supplementary Tables 1 and 2). We further excluded hits, for
which the scoring shRNAs displayed poor knockdown (KD)
efﬁciency and selected four enriched hits (Rbm25, Sfrs12ip1,
Hnrnph1, and Prpf40a) and ﬁve depleted hits (Cpsf1, Cpsf6,
Hnrnpab, Rbpms2, and Xab2) (Fig. 1c) for in vivo validation. To
this end, we carried out in vivo competitive bone marrow
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-08076-y
2 NATURE COMMUNICATIONS |          (2019) 10:172 | https://doi.org/10.1038/s41467-018-08076-y | www.nature.com/naturecommunications
transplantations (BMT) using Lp30 donor cells transduced with
target-speciﬁc shRNA constructs coexpressing GFP along with
YFP-expressing nontargeting (scrambled) shRNA-transduced
competitors (Fig. 1d, see KD efﬁciencies in Supplementary
Fig. 1e). In this assay, KD of Rbm25 and Hnrnph1 gave rise to
signiﬁcant enrichment of cells transduced with either of the two
target-speciﬁc shRNAs over their scrambled shRNA-transduced
counterparts (Fig. 1e), thus recapitulating the phenotype from the
Lp30 leukemic BM
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Fig. 1 Pooled in vivo shRNA screen for essential splicing factors in the Lp30 AML model. a Relative proportions of splicing factor categories represented in
the shRNA library. b Schematic outline of the in vivo shRNA screen (left panel) and the in vivo GFP/YFP competitive assay used to functionally validate
candidates (right panel). In the screening procedure, sublethally irradiated recipients were transplanted with library-transduced Lp30 AML cells and
allowed to develop AML, after which the relative representation of the individual shRNA inserts in output vs. input cells was assessed. For validation, cells
transduced with candidate-speciﬁc shRNA/GFP and scrambled shRNA/YFP-expressing retrovirus were mixed and injected into recipients who developed
AML, after which GFP/YFP ratios in output vs. input cells were quantiﬁed by ﬂow cytometry. c Results of screens carried out in Lp30 AML cells (upper
panel) and normal c-Kit+ cells (lower panel). The log2 fold changes in the representation of individual shRNAs in output vs. input samples are indicated.
shRNAs targeting selected candidate genes are highlighted. d Representative example of GFP+ and YFP+ cells in input vs. output AML cells from the
in vivo validation of Rbm25. e, f In vivo validation of candidate shRNAs, which were either enriched (e) or depleted (f) in the Lp30 screen (c). Data
represent the mean ± s.d. (n= 4 for each group). Data were subjected to an unpaired t test, and asterisks indicate the following: *P < 0.05; **P < 0.01. Panel
(e) shows representative results of two independent experiments for Rbm25. All replicates in e and f are biological replicates
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in vivo screen. KD of Sfrs12ip1 and Prpf40a displayed similar
trends, albeit not with signiﬁcant FC differences. Of the ﬁve
depleted hits, Cpsf6 and Hnrnpab showed strong depletion as
observed in the screen (Fig. 1f). However, in contrast to what we
observed in the c-Kit+ screen, in vitro competitive assays on
normal c-Kit+ cells (Supplementary Fig. 1f) demonstrated that
KD of the two targets also led to a gradual depletion of normal
hematopoietic cells over time (Supplementary Fig. 1g). Therefore,
these candidates were not selected for further studies.
In summary, we have used an in vivo shRNA screening
approach to identify two splicing factors with tumor suppressive
characteristics in the murine Lp30 AML model.
Rbm25 KD accelerates leukemogenesis in murine AML. Among
our validated tumor suppressor hits, Rbm25 KD yielded the most
prominent effect on Lp30 AML cells compared to c-Kit+ control
cells (Fig. 1d, e, see Supplementary Fig. 1h and i for the KD
efﬁciency of all four shRNAs in the library), and we therefore
forwarded RBM25 for functional analysis. RBM25 is ubiquitously
expressed in the entire myeloid lineage (Supplementary Fig. 1j
and k) and encodes an RNA-binding protein involved in pre-
mRNA processing19. The protein has previously been implicated
in regulation of apoptosis by affecting the balance between the
anti- and pro-apoptotic transcripts of the BCL2L1 gene encoding
the key apoptotic regulator BCL-X20,21. Yet any role for RBM25
in a leukemic context has not been studied, thus making it a valid
focus of further investigation.
We ﬁrst assessed if Rbm25 KD impacted on survival of mice
transplanted with Lp30 AML cells. To this end, we transplanted
10,000 FACS sorted GFP + Lp30 cells into irradiated recipients
and indeed found that mice transplanted with leukemic cells
expressing Rbm25 shRNAs lived signiﬁcantly shorter than control
mice (36.5 days vs. 43.5 days; Fig. 2a). Furthermore, Rbm25 KD
cells led to increased colony formation in semi-solid media
(Fig. 2b).
To test if the effects of Rbm25 KD were maintained during
serial transplantation, we carried out a competitive transplanta-
tion experiment with secondary donor cells (Supplementary
Fig. 2a). As for the primary transplantations, we observed a
strong enrichment of Rbm25 KD cells vs. competitors (Fig. 2c),
thus conﬁrming an in vivo role of Rbm25 KD in Lp30 AML.
To rule out that the tumor suppressive effect of RBM25 was
restricted to the Lp30 AML model, we carried out an in vitro
competitive (GFP/YFP) assay using a murine MLL-AF9 fusion-
driven AML model22. Coculture of the mixed cells resulted in a
2–4-fold enrichment of Rbm25 KD cells compared to control cells
over an 8-day period (Fig. 2d). Importantly, we did not observe
any growth advantage in normal c-Kit+ progenitor cells following
Rbm25 KD (Fig. 2e) and no difference was observed in their
colony-forming unit (CFU) capacity (Fig. 2f). Efﬁcient Rbm25
KD in all cellular contexts was conﬁrmed both at mRNA and
protein levels (Supplementary Figure 2b and c).
In conclusion, our results demonstrated that reduced expres-
sion of RBM25 can potentiate growth of at least two murine AML
subtypes. This effect is absent in normal hematopoietic
progenitor cells and thus demonstrates that RBM25 exerts a
tumor suppressive function in murine AML.
RBM25 restricts growth of human leukemic cell lines. Having
shown that RBM25 acts as a tumor suppressor in murine AML,
we now wanted to test if we could expand this to a human setting.
To do so, we ﬁrst transduced the U937 cell line (cells with
myeloid characteristics and unknown mutational status derived
from a patient with histiocytic lymphoma) with lentiviral shRNA
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Fig. 2 Functional validation of Rbm25 in murine AML. a Kaplan−Meier survival analysis of mice injected with AML cells transduced with the indicated
shRNAs (n= 8, log-rank test, *P < 0.05). b Colony-forming assay performed on Lp30 cells transduced with shScr or shRbm25. 3000 GFP+ cells were
sorted and plated in MethoCult M3434 medium 2 days after transduction (data represent the mean ± s.d., n= 3). c The effects of shRbm25 on tumor
growth in a serial in vivo competitive BM transplantation assay (data represent the mean ± s.d., n= 4). d, e Competitive assays performed on d MLL-AF9
and e c-Kit+ BM cells transduced with shScr or two individual shRNA targeting Rbm25. Graph shows the GFP/YFP ratio over time normalized to input
mixture. f Colony-forming potential of normal c-Kit+ BM cells transduced with shScr or shRbm25. Cells were plated in M3434 semi-solid medium 2 days
after transduction (data represent the mean ± s.d., n= 3). Data were subjected to an unpaired t test, and asterisks indicate the following: *P < 0.05; **P <
0.01; ****P < 0.0001. Panels (b), (d), (e) and (f) show representative results of two independent experiments. All replicates in (b)−(f) are biological
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vectors targeting RBM25 and tested the effects on proliferation
(Fig. 3a, b). Knockdown of RBM25 accelerated growth both when
assayed in terms of the accumulation of cell numbers (Fig. 3b)
and in a label-retaining assay following incubation with carbox-
yﬂuorescein diacetate succinimidyl ester (CFSE) (Fig. 3c and
Supplementary Fig. 3a). Moreover, when we plated U937 cells in
methylcellulose, RBM25 KD increased their CFU potential and
promoted the formation of larger colonies (Fig. 3d). The increase
in colony numbers could be rescued by ectopic expression of an
shRNA-resistant variant of RBM25, demonstrating that the pro-
proliferative effects of RBM25 KD were not caused by off-targets
effects (Fig. 3e, f). To further validate the growth inhibitory effects
of RBM25, we used CRISPRi-mediated gene silencing in which
the noncutting dCAS9-KRAB fusion protein is targeted to the
RBM25 promoter using speciﬁc guide RNAs. Consistent with the
shRNA KD phenotype, CRISPRi-mediated gene silencing of
RBM25 increased the proliferation of U937 cells in suspension as
well as their CFU potential (Supplementary Fig. 3b–d).
In order to gain further insights into the cellular events
underlying the growth advantage following downregulation of
RBM25, we analyzed the cell cycle status and apoptotic proﬁles of
control and RBM25 KD U937 cells. Speciﬁcally, we found that
RBM25 KD decreased the number of cells in the G0/G1 phase,
whereas more cells accumulated in the S/G2/M phase (Fig. 3g).
This indicated that cell cycle transition was accelerated upon
RBM25 KD, a phenomenon accompanied by a dramatic
reduction in the fraction of Annexin V+ apoptotic cells (Fig. 3h).
In addition, RBM25 KD in the t(8;21) AML cell line, Kasumi-1,
resulted in similar proliferation and apoptotic phenotypes as
those observed in U937 cells (Supplementary Fig. 3e–g)
Overall, these data demonstrate that the tumor-suppressive
function of RBM25 that we originally observed in murine AML
models can be extended to at least two distinct human models
and identiﬁes RBM25 as cross-species regulator of proliferation
and apoptosis.
RBM25 maintains distinct gene expression programs. In order
to gain mechanistic insights into RBM25 function, we next per-
formed RNA-sequencing (RNA-seq) on U937 cells transduced
with scrambled or RBM25-speciﬁc shRNAs and obtained a pro-
minent separation between the transcriptional proﬁles of the two
groups (Supplementary Fig. 4a). Overall, we found 2718 differ-
entially expressed genes with equal numbers of up- and down-
regulated genes (adjusted q < 0.05; Supplementary Data 2). To
explore the potential perturbation of speciﬁc molecular pathways
after RBM25 KD, we applied gene set enrichment analysis
(GSEA)23. Gene sets associated with loss of stemness (in either
leukemic or normal hematopoietic stem cells), myeloid differ-
entiation and apoptosis were depleted in RBM25 KD cells,
whereas the opposite was true for MYC targets genes and gene
sets implicated in cell cycle progression (Fig. 4a). The de-
regulation of genes associated with cell cycle and apoptosis sup-
port the phenotypic analysis in both human and murine cells
(Fig. 3g, h).
As described above, the GSEA suggested that RBM25 may
impact on the balance between stemness/self-renewal on one
hand and differentiation on the other. In order to directly address
this possibility, we took advantage of the recently described 8227
cell culture system, derived from a relapse AML patient. These
cells maintain a leukemic hierarchy in culture in which LSCs,
progenitors, and blasts can be identiﬁed based on CD34 and
CD38 expression24. 8227 cells were transduced with either
RBM25-targeting shRNA or scrambled control, and the relative
distribution of the CD34+CD38− (LSC), CD34+CD38+ (pro-
genitor) and CD34− (blast) populations was assayed. In line with
the GSEA, downregulation of RBM25 led to signiﬁcant expansion
of the LSC and progenitor compartments at the expense of
mature cells (Fig. 4b). In concordance with our observations in
U937 cells, the proportion of cells in the S/G2/M phase increased
within the two immature populations, while the opposite was
the case for cells in the G0/G1 phase (Fig. 4c and Supplementary
Fig. 4b). The pro-differentiation effect of RBM25 was also
supported by analysis of murine Lp30 AML samples in vivo,
where we observed a signiﬁcant increase in the c-Kit (hemato-
poietic stem- and progenitor marker) to Mac1 (myeloid
differentiation marker) ratio in engrafted BM Lp30 cells
expressing low levels of Rbm25 (Supplementary Fig. 4c).
In summary, the gene expression analysis conﬁrms the
observed cell cycle accelerating and anti-apoptotic phenotypes
of RBM25 KD cells. Furthermore, RBM25 appears to restrict the
self-renewal and/or promote the differentiation of immature
leukemic cells which is consistent with the tumor suppressive
function of the protein.
RBM25 regulates the splicing of speciﬁc pre-mRNAs. Although
the role of RBM25 as a splicing regulator is relatively unchar-
acterized, it has previously been demonstrated to regulate the
balance between the pro- and anti-apoptotic functions of BCL-X
by affecting splicing of the BCL2L1 pre-mRNA20. In line with this
known function of RBM25, we indeed ﬁnd that the reduction in
apoptosis of RBM25 KD U937 cells is accompanied by changes in
the levels of the pro- and anti-apoptotic BCL2L1 isoforms,
effectively changing the balance in favor of apoptotic prevention
(Fig. 5a). RNA immunoprecipitation (RIP) experiments demon-
strated a selective interaction between RBM25 and the BCL2L1
transcript, which desensitized cells to ABT-263 (Navitoclax), a
selective inhibitor of BCL2 family proteins (Fig. 5b, c). Finally,
when we scrutinize an RNA-seq AML dataset from The Cancer
Genome Atlas (TCGA)25, we ﬁnd that low levels of RBM25 favor
a relative high expression of the anti-apoptotic BCL2L1 isoforms
(Fig. 5d). This suggests that RBM25 plays a role in regulating
BCL-X function in primary AML patients and that RBM25
expression levels may be used to predict response to Navitoclax
and other BH3-mimetics in AML.
While the ﬁndings described above mechanistically explain
parts of the RBM25 KD phenotype, we suspected that RBM25
may also control the levels and/or functions of other regulators of
cell proliferation and cell death. In an attempt to uncover these,
we subjected our RNA-seq data to the previously reported
analytical pipeline SpliceR26 with the aim of identifying
alternatively spliced isoforms. This led to the identiﬁcation of
338 signiﬁcantly deregulated transcripts and among these, we
noted a prominent increase in the expression of the exon 12
including variant of BIN1 following KD of RBM25 (Fig. 6a and
Supplementary Data 3). Quantiﬁcation of the SpliceR output
conﬁrmed that RBM25 KD promoted a marked increase in the
relative contribution of the BIN1 (+12) isoform to the total BIN1
mRNA pool which also increased (Fig. 6b and Supplementary
Fig. 5a). The RNA-seq data were further corroborated by RT-PCR
(Fig. 6c), and expression of the BIN1(+12) isoform at the protein
level was conﬁrmed by western blotting analysis (Fig. 6d).
BIN1 acts as tumor suppressor through its ability to inhibit
MYC activity27; however, the inclusion of exon 12 leads to the
introduction of an extra domain, which negatively affects the
BIN1−MYC interaction via intra-protein steric hindrance28,29.
To assess whether the effects of RBM25 KD on cell proliferation
are regulated directly by altered BIN1(+12) expression, we
speciﬁcally knocked down BIN1(+12) expression using an
shRNA targeting the exon 12 sequence, without a marked effect
on the isoforms lacking this exon (Supplementary Fig. 5b).
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Strikingly, CFU assays revealed that KD of the BIN1(+12)
isoform almost completely rescued the previously demonstrated
effect of RBM25 KD (Fig. 6e). Moreover, the BIN1 mRNA
transcripts could be speciﬁcally immunoprecipitated by an
RBM25 antibody suggesting that RBM25 represses the inclusion
of exon 12 sequences via direct interactions with BIN1 pre-
mRNA (Fig. 6f).
Taken together, we showed that RBM25 controls the functional
properties of not only known targets (BCL-X) but also previously
uncharacterized targets such as BIN1 via an alternative splicing
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mechanism. Importantly, targeting the BIN1 exon 12 variant
rescued the RBM25 KD phenotype.
RBM25 knockdown activates MYC targets through BIN1. MYC
is a key oncogene that controls several cellular pathways relevant
to cancer, including cell cycle entry, ribosome synthesis, and
various metabolic processes. Indeed, overexpression of MYC is
one of the most common drivers of many cancer types30,
including AML31. As shown above, KD of RBM25 de-repressed
an alternatively splicing event and resulted in the inclusion of
exon 12 in the BIN1 pre-mRNA and KD of this variant rescued
the RBM25 KD phenotype. Since BIN1(+12) has been shown to
lack the ability to interact with MYC27,29,32, we hypothesized that
the MYC pathway may be activated and that this potentially
could underlie the RBM25 KD phenotype. In accordance with the
known posttranslational effect of BIN1 on MYC function33, we
found that MYC protein levels were unchanged following RBM25
KD (Fig. 7a). As reported above MYC targets were upregulated
upon RBM25 KD (Fig. 4a). In particular, we detect a notable
increase in the expression of genes associated with cell cycle
(CDK4, CDK6), protein synthesis (EIF2A, EIF4E2), energy
metabolism (LDHA), and DNA metabolism (CAD), all of which
functionally cooperate to promote cell growth34. The de-
regulation of these genes was validated both by shRNA and
CRISPRi-mediated downregulation of RBM25 (Fig. 7b and Sup-
plementary Fig. 5c) and their MYC-dependency veriﬁed by MYC
KD (Fig. 7c). Importantly, we showed that KD of the BIN1(+12)
isoform also partially reduced the expression of the selected MYC
target genes, thus demonstrating that the effect of RBM25 KD is
mediated by the BIN1(+12) isoform (Fig. 7d).
Next, we wanted to assess how the RBM25-BIN1 pathway
affected MYC function. The observed RBM25 KD-mediated
increase in the expression of MYC target genes, in the absence of
changes in MYC levels, is consistent with a model where RBM25
levels modulated the transcriptional activity of MYC through the
control of BIN1 isoform distribution. To test this model, we
cotransfected an MYC-responsive transcriptional reporter con-
struct into U937 cells and demonstrated robust MYC-driven
reporter expression which could be abrogated by mutation of the
MYC binding sites. The MYC-responsive reporter expression was
indeed increased by RBM25 KD, and this increase was partly
suppressed by the BIN1(+12)-speciﬁc shRNA (Fig. 7e). Finally,
we showed that the increased MYC transcriptional activity
induced by RBM25 KD facilitated a modest but signiﬁcant
increase in the tolerance of U937 cells to 10058-F4, an inhibitor of
the MYC−MAX interaction (Fig. 7f).
Collectively, we have shown that RBM25 KD promotes
inclusion of exon 12 of the BIN1 pre-mRNA. This BIN1(+12)
isoform acts as a dominant-negative variant leading to increased
MYC transcriptional activity which in turn accelerates leukemic
proliferation. These ﬁndings support a model where RBM25
controls MYC transcriptional activity via BIN1.
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RBM25 as a prognostic factor in AML. Our results so far have
uncovered a tumor-suppressive function of RBM25 in murine
AML and in human cell lines. To determine if RBM25 also
inﬂuenced AML patient outcome, we evaluated the prognostic
value of RBM25 mRNA expression using a TCGA RNA-seq AML
dataset and associated patient survival data25. Notably, we found
that low RBM25 levels were associated with signiﬁcantly worse
overall survival (OS), consistent with a tumor-suppressive func-
tion in human AML (Fig. 8a). To investigate whether low RBM25
levels are associated with particular AML subtypes, we carried out
the aforementioned analysis on speciﬁc mutations belonging to
previously deﬁned subclasses3 in patients displaying the 10%
lowest vs. highest levels of RBM25 (Supplementary Figure 6a).
This analysis revealed that low-expressing patients displayed a
lower mutational load and a complete absence of the APL-
associated t(15;17) translocation. Both observations ﬁt well with
our demonstration that RBM25 KD results in accelerated tumor
progression and delayed myeloid differentiation. It is tempting to
propose that the reduced proliferation associated with high
RBM25 levels necessitates additional mutational events to sustain
AML. Conversely, the t(15;17) translocation is associated with
favorable prognosis3 and a relatively differentiated phenotype,
thus explaining the observed mutual exclusion of low RBM25
expression and the t(15;17) translocation.
To address a possible link between RBM25 and BIN1(+12)
expression in AML patients, we next assessed the expression of
BIN1(+12) in patients displaying the 10% highest vs. lowest
RBM25 levels. Consistent with our functional data, this analysis
demonstrated an inverse correlation between BIN1(+12) and
RBM25 (Fig. 8b). Finally, we observed an inverse correlation
between the expression of RBM25 and an MYC target signature
(Fig. 8c), consistent with our in vitro data demonstrating that
RBM25 KD facilitates the upregulation of an MYC-driven
transcriptional program.
Finally, to address whether a concomitant decrease in RBM25
expression and activation of MYC targets is associated with
speciﬁc AML subtypes we partitioned the TCGA dataset into two
distinct groups: Group 1 contains patients which display low
expression of RBM25 (low 25% percentile) and high level of MYC
target gene expression (MYC target gene score > median) and
Group 2 containing patients with the opposite characteristics. We
subsequently assessed which genetic lesions were differentially
represented between them (Supplementary Fig. 6b). This analysis
revealed that mutations in epigenetic modiﬁers and NPM1 were
overrepresented (albeit not signiﬁcantly for the latter) in samples
with low RBM25 expression and high MYC score, whereas the
opposite was the case for t(15;17) and t(8;21) translocations. The
trend towards overrepresentation of NPM1 mutations in samples
with low RBM25 expression and high MYC score is potentially
interesting, since the NPM1 gene has previously been shown to be
a direct MYC target35,36. It is tempting to speculate that an
increased trans-activation potential of MYC resulting from low
RBM25 expression may promote increased NPM1 levels which
may, in turn, provide a selective pressure for the acquisition of
NPM1 LOF mutations.
Collectively, these data suggest that the RBM25−BIN1−MYC
axis is of functional importance not only in murine AML and
human leukemic cell lines, but also in primary human AML.
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Discussion
Pre-mRNA splicing is a key process with the potential to impact
on all cellular pathways. Recent cancer sequencing efforts have
uncovered splicing factors as being frequently mutated in
hematological malignancies, including MDS and AML, and pre-
mRNA splicing is frequently deregulated in these diseases. Here,
we have used an in vivo shRNA screening approach in a murine
AML model in order to identify novel splicing regulators which
act as tumor-promoting or -suppressing factors in AML. Among
several validated candidates, we focused on RBM25 which we
demonstrated to have tumor-suppressive properties in two
murine AML models, two human myeloid cell lines and in the
hierarchical organized 8227 AML cell culture system. In contrast,
no effects could be demonstrated of knocking down the gene in
normal murine hematopoietic cells. Mechanistically, the anti-
proliferative effect of RBM25 correlated with delayed cell cycle
progression, increased apoptosis and accelerated myeloid differ-
entiation. In addition, RBM25 restrict both CFU and LSC num-
bers in U937 and 8227 cultures, respectively, suggesting that its
main function is to act on the most primitive leukemic cells.
RBM25 is a poorly characterized RNA binding protein that has
previously been implicated in speciﬁc splicing events in human
heart failure and as a crucial factor for plant growth and abiotic
stresses in Arabidopsis37–39. A recent study using CRISPR/CAS9-
mediated knockout demonstrates that complete loss of RBM25 is
detrimental to growth of human cancer cell lines and leads to
widespread deregulation of pre-mRNA splicing40. In the context
of our work, this suggests that the impact of RBM25 on pro-
liferation, apoptosis, and splicing is not only highly dose-
dependent but may also be cell-type-dependent. Interestingly,
recurrently heterozygously mutated splicing factors in hemato-
logical malignancies (such as SRSF2 and SF3B1) are associated
with embryonic lethality following their complete deletion in
mice41,42. Thus, the concept of a (near-) essential splicing reg-
ulator having tumor-promoting functions at reduced levels, as
reported in the present work, suggest that AML (and perhaps
other cancer cells) cells tolerate a reduction in essential splicing
function, if these are counteracted by beneﬁcial events such as
those reported here. In further support of its tumor suppressor
function, RBM25 was previously found to be mutated in breast
cancer and to favor the expression of the pro-apoptotic isoform of
the BCL2L1 pre-mRNA, the latter via its role in 5ʹ splice site
selection in the context of the U1 snRNP20,43,44.
In the present work, we also showed that RBM25 abrogates the
inclusion of exon 12 in the BIN1 pre-mRNA, thus preventing the
generation of the dominant-negative BIN1 isoform which is
unable to repress MYC activity. Indeed, shRNA-mediated
downregulation of the BIN1(+12) transcript partly rescued the
increase in growth, CFU activity and expression of MYC target
genes induced by downregulation of RBM25. Given the well-
known pro-proliferative role of MYC in many settings, the
increase in MYC activity therefore seems to underlie the accel-
erated cell cycle progression following RBM25 KD. Moreover,
MYC has also been reported to be important for LSC function
which again is consistent with our ﬁndings of increased LSC
numbers in the 8227 system and the increase in CFU activity in
U937 cells following RBM25 KD45,46.
Overall, our data suggest a model where the control of MYC
activity is a core function of RBM25 and that it is part of mole-
cular rheostat to keep MYC activity under control in normal cells
(Fig. 8d). Interestingly, the proposed MYC rheostat is further
protected by the impact of RBM25 on splicing of the BCL2L1 pre-
mRNA. Speciﬁcally, although MYC is a growth-promoting
oncogene, its overexpression in normal cells is associated with
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apoptosis, and MYC-dependent tumors therefore have to disable
apoptotic pathways47. Thus by favoring the expression of the pro-
apoptotic BCL-XS isoform, RBM25 provides the system with a
fail-safe mechanism in case of MYC activation by RBM25-
independent means. The proposed MYC rheostat may also be
important during normal development in order to control MYC
activity and thereby avoid overgrowth of particular cell types.
In leukemia, downregulation of RBM25 allows premalignant or
malignant cells to harvest the pro-proliferative beneﬁts of MYC
(via expression of the BIN(+12) isoform), while at the same time
escaping apoptosis (via a shift towards the anti-apoptotic BCL-
XL). The proposed MYC rheostat also appears to be of clinical
relevance. Speciﬁcally, in AML patients, we showed that RBM25
low-expressing patient samples express high levels of the BIN
(+12) isoform, high levels of MYC target genes and are associated
with a particular poor outcome and speciﬁc AML subtypes. Thus,
modulation of RBM25 levels or activity may constitute a potential
therapeutic option in a subset of AML patients.
Does the RBM25-BIN1-MYC pathway identiﬁed in the present
work play a role in other cancers? Given that MYC deregulation is
a hallmark of many cancers, we hypothesize that at least some of
these events are caused by derepression of MYC via the RBM25
−BIN1−MYC pathway. Given that this pathway operates at the
posttranscriptional levels, these cancers would not display altered
levels ofMYC transcript but will be characterized by the increased
expression of downstream MYC targets. This hypothesis is sup-
ported by data from melanoma where tumor development is
associated with the expression of BIN(+12) variant which was
further demonstrated to be unable to inhibit MYC-mediated
malignant transformation29. The extent to which this observation
can be expanded to other tumor types is currently under
investigation.
In summary, we have used an in vivo shRNA screening
approach to uncover a novel splicing-dependent mechanism for
the control of MYC activity which appears to be operative in
primary cancer. To the best of our knowledge, this represents one
of the few examples where speciﬁc splicing events have been
demonstrated to underlie the phenotype resulting from splicing
factor deregulation in a relevant disease context. As such our
studies suggest that disease-relevant splicing factors expand
beyond those that are found to be recurrently mutated in diseases
like cancer.
Methods
Animal studies. B6.SJL recipients (all female, 10–15 weeks of age), preconditioned
by a sublethal (500 cGy) dose of gamma-irradiation 17 h prior to transplantation,
were injected intravenously (IV) with Lp30 AML cells. In order to progress the
Lp30 model18 to an aggressive state with short latency and high penetrance, we
further enriched for LSCs activity by serial transplanting leukemias through sec-
ondary and tertiary recipients.
Competitive BMT assay: 105 transduced target-speciﬁc-shRNA-GFP-positive
cells were mixed in a 1:1 ratio with shScr-YFP-positive cells and transplanted into
sublethally irradiated recipients who were sacriﬁced after 4 weeks. For serial
competitive BMT assay, shRbm25-GFP and shScr-YFP (in the pMLS backbone)-
positive cells were harvested from the primary transplanted CD45.2+ mice 3 weeks
after injection and mixed in a 1:1 ratio. Fifty thousand cells were transplanted into
sublethally irradiated recipient CD45.1+ mice who were sacriﬁced and assayed
after 3 weeks.
Survival assay: Sublethally irradiated recipients were transplanted with 10,000
transduced and sorted GFP+ Lp30 cells along with 4.5×105 cells/mouse irradiated
(2000 cGy) BM cells as support.
In all experiments, recipient mice were randomly assigned to receive different
experimental transplants and mice were shufﬂed between cages. No blinding was
performed. Control and test groups contain 4−8 mice each and group size was not
predetermined. No animals were excluded from analysis. Mice were monitored on
a daily basis for disease progression and sacriﬁced when they became moribund.
All mouse experiments were conducted according to protocols approved by the
Danish Animal Ethical Committee.
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Generation of splicing factor pMLS library. In total, 613 shRNAs targeting 230
known or putative splicing factor genes (full list is provided in Supplementary
Data 1) in the pGIPZ vector (Dharmacon) were subcloned into pMLS (MSCV-
LTRmir30-SV40-GFP)48 with XhoI and EcoRI.
Retrovirus production and transduction. Retroviral supernatants were generated
by CaPO4-mediated transfection of Phoenix E cells. Forty-eight hours post-
transfection, cell supernatants were harvested, ﬁltered through 0.45 µm acrodisc
syringe ﬁlters (Pall), and frozen for storage. Pooled retrovirus supernatants for
screening were generated by pooling equal amounts of the pMLS constructs prior
to transfection.
For transduction, retroviral supernatant (800 µl/well) was added onto retronectin
(Takara)-coated nontissue culture treated 24-well plates and centrifuged at 2000 × g
for 50 min at 32 °C. After aspiration of the supernatant, cells were seeded at a
density of 1×106/well. The transduction was repeated the following day, and the
cells were cultured for 24 h prior to Fluorescence Activated Cell Sorter (FACS)
sorting of transduced (GFP+) cells.
Cell culture conditions. Lp30 AML cells were cultured in X-vivo 15 media (Lonza)
supplemented with 50 ng/ml murine stem cell factor (SCF), 50 ng/ml human
interleukin-6 (IL-6), 10 ng/ml murine interleukin-3 (IL-3) (all from Prepotech), 1%
bovine serum albumin (Stem Cell Technologies), 0.1mM β-mercaptoethanol (Sigma-
Aldrich), 1% L-glutamine (Gibco), and 1% penicillin/streptomycin (pen/strep, PAA).
Wild-type BM cells were enriched for c-Kit+ cells by incubation with anti-
CD117 microbeads (Miltenyi Biotec) and subsequent separation on MACS LS
columns (Miltenyi Biotec). c-Kit+-enriched cells were grown in RPMI-1640
medium (Life Technologies) supplemented with 20% fetal bovine serum (Hyclone),
20% WEHI conditioned medium, 20 ng/ml SCF, 10 ng/ml IL-6, and 1% pen/strep.
MLL-AF9 cells were derived from a primary MLL-AF9-transduced murine AML49
and grown using the same conditions as for c-Kit+ cells.
For in vitro competitive assays on c-Kit+ cells and MLL-AF9 cells, target-
speciﬁc shRNA-GFP-positive cells were mixed in a 1:1 ratio with corresponding
shScr-YFP positive cells and seeded at a density of 600,000 cells/ml. Cells were kept
subconﬂuent and counted and re-seeded every second day.
U937 cells were grown in RPMI-1640, GlutaMAXTM supplement medium
(Thermo Fisher Scientiﬁc) containing 10% fetal calf serum (FCS) (HyClone) and
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1% penicillin/streptomycin (Thermo Fisher Scientiﬁc). Kasumi-1 cells were grown
in RPMI-1640, GlutaMAXTM supplement medium (Thermo Fisher Scientiﬁc)
containing 20% FCS (HyClone) and 1% penicillin/streptomycin (Thermo Fisher
Scientiﬁc).
Early passage 8227 cell cultures were grown in StemSpan SFEM II (Stem
Cell Technologies) supplemented with Flt3-L (50 ng/ml), IL-3 (10 ng/ml), SCF
(50 ng/ml), IL-6 (10 ng/ml), granulocyte colony-stimulating factor (10 ng/ml),
thrombopoietin (25 ng/ml) (all from Miltenyi Biotec SE)24. Individual cultures
were passaged every 6–7 days and monitored by ﬂow cytometry using CD34 and
CD38. U937 and kasumi-1 cells were purchased from the American Type Culture
Collection (ATCC). All cell lines used have been tested for Mycoplasma.
In vivo pooled shRNA screening. In vivo screening on Lp30 murine AML cells
was carried out by transducing Lp30 cells with subpools (150 shRNAs) of shRNA
expressing retrovirus. Transduced cells were injected (IV) into sublethally irra-
diated recipient mice in numbers corresponding to at least 500,000 GFP+ cells
(assessed by FACS analysis prior to injection). Recipient mice were sacriﬁced, and
BM cells were harvested 4 weeks after transplantation.
In the in vitro screen carried out on c-Kit+ cells, the entire splicing factor
library containing 613 shRNAs was used to transduce two million c-Kit+-enriched
BM cells which were kept in culture for 7 days after transduction. The shRNA
hairpin region was PCR ampliﬁed from puriﬁed genomic DNA using primers
carrying Illumina adaptors and barcodes (Supplementary Table 3) under the
following conditions: 1 μl 10 μM primary PCR primer mix, 1 μl 10 mM dNTP mix,
1 μl 10× HiFi buffer, 0.2 μl of Platinum® Taq DNA polymerase (Invitrogen) and
1 μg genomic DNA in a total reaction volume of 50 μl. Reactions were subjected to
94 °C for 30 s and then run 40 cycles of 94 °C for 30 s, 62 °C for 30 s and 68 °C for
25 s followed by 68 °C for 5 min. PCR products were then gel-puriﬁed and
subsequently sequenced on Illumina HiSeq 2500 system.
Sequencing reads were de-multiplexed and mapped using bowtie2 50 onto an
shRNA library pseudogenome as previously described49. The raw sequencing
counts were normalized to the total number of reads for each replicate. The fold
change was calculated as the ratio of normalized reads between the two time points,
divided by the normalized reads of control shRNAs.
Colony-forming assays of murine cells. FACS sorted transduced cells were plated
on MethoCult M3434 (Stemcell Technologies). Colonies were scored after 14 days
by light microscopy.
DNA constructs and cloning. For experiments in human cells, we used a lentiviral
vector (pLKO.1-puro, Sigma-Aldrich) expressing shRNA targeting RBM25. An
shRNA-resistant RBM25 variant (RBM25-R, with mutation of C1425T, T1428C,
G1431A, T1434C, A1440G) was generated from a human RBM25 open reading
frame (ORF) pDONR223 vector (Clone ID: BC136775-ORF, TransOMIC) using
the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies)
according to the manufacturer’s instructions. Successful mutagenesis was con-
ﬁrmed by Sanger sequencing, and the mutant RBM25 ORF was introduced into the
lentiviral expression vector pLX304 (Addgene plasmid # 25890) using gateway
cloning.
For RBM25 guide RNA (gRNA) cloning (sequences are listed in Supplementary
table 4), oligos were phosphorylated, annealed and ligated into BsmBI digested
pLKO5.sgRNA.EFS.GFP (Addgene plasmid # 57822).
shRNA targeting BIN1(+12) and MYC (sequences are listed in Supplementary
Table 4) were cloned into pLKO.3G (Addgene plasmid #14748). All restriction
enzymes were purchased from NEB and used according to the manufacturer’s
instructions. pHR-SFFV-KRAB-dCas9-P2A-mCherry was from Addgene (plasmid
# 60954).
The MYC reporter plasmid pBV-Luc wild-type (wt) MBS1–4 (Addgene,
plasmid #16564) contains four tandem MYC binding sites from the human CDK4
promoter located upstream of Fireﬂy luciferase. pBV-Luc mut MBS1–4 (Addgene,
plasmid 16565), which has all four MYC binding sites mutated was used as a
negative control. pRL-SV40 (Promega) is a Renilla luciferase-expressing plasmid
that was used as an internal control in the dual luciferase assay.
Lentivirus production and transduction human cells. Lentivirus was produced
by CaPO4-mediated transfection of HEK-293FT cells with 4 µg of pCMV-VSV-G,
8 μg of PAX8 packaging plasmid, and 10 μg of the lentiviral vector plasmid. Pro-
duction of viral supernatants and transduction was carried out as with retroviral
constructs. Cells transduced with pLKO-puro constructs were selected using 2 μg/
ml of puromycin (Sigma) for 3 days, whereas pLX304-blasticidin transduced cells
were selected using 5 μg/ml blasticidin (Thermo Fisher Scientiﬁc) for 5 days.
Cell growth, CSFE assay, and colony-forming assays of human cells. Cells were
transduced as described above and plated at 100,000 cells/ml for proliferation
assays. Cell proliferation was either assessed directly by counting or indirectly by
CFSE staining using the CellTrace™ CFSE Cell Proliferation Kit (Thermo Fisher
Scientiﬁc) according to the manufacturer’s protocol. For colony-forming assays,
transduced cells were FACS sorted and plated on MethoCult H4434 (Stemcell
Technologies). Colonies were scored after 12 days by light microscopy.
Flow cytometry analysis and cell sorting. Cell sorting was carried out on
FACSAriaI or FACSAriaIII (BD Biosciences), whereas analytical stains were
assessed on LSRII or FACSCalibur (BD Biosciences).
Retrovirally transduced murine cells were washed with FACS buffer (3% FCS in
phosphate buffer saline (PBS)), and stained with 7-AAD (Invitrogen, 1:1000) to
exclude dead cell prior to sorting or analyzing for GFP/YFP expression. For surface
marker analysis, BM cells collected from tibia, femur, and ilium were washed with
FACS buffer, and stained for 15 min at 4 °C using the following antibody cocktails:
CD45.2-PE-eFlour610 (eBioscience, clone 104, 1:50), CD45.1-PECy7 (eBioscience,
clone A20, 1:50), CD11b-APC (eBioscience, clone M70, 1:800), c-Kit-eFlour780
(eBioscience, clone 2B8, 1:200). Gating strategy as in Supplementary Fig. 4c. For
human cell lines cell cycle analysis: Cells were ﬁxed, permeabilized, and stained with
PI (Invitrogen). For human cell line apoptosis analysis: cells were washed with FACS
buffer (3% FCS in PBS), and stained using PE Annexin V apoptosis Detection kit
(BD Biosciences), according to the manufacturer’s recommendations. For 8227 cells
LSC/progenitor/blast population analysis: cells were washed with FACS buffer
(3% FCS in PBS), and stained with CD34-APC (BD Biosciences, clone 581, 1:200)
and CD38-PE (BD Biosciences, clone HB7, 1:50).
All ﬂow cytometry data were analyzed using the FlowJo 10.1 software (Treestar,
Ashland, OR, USA).
RNA extraction, cDNA synthesis, and qPCR analysis. RNA was extracted using
the AllPrep DNA/RNA Mini kit (Qiagen) following the manufacturer’s instruction.
cDNA was synthesized by ProtoScript cDNA synthesis kit (New England Biolabs).
Real-time PCR reactions were performed on a LightCycler 480 (Roche) using SYBR
Green I PCR Master Mix (Roche). Expression was normalized to the housekeeping
genes Rpo or Actg1 for murine cells, and GAPDH or H6PD for human cells. All
primers used are listed in Supplementary Information as Supplementary Table 5.
Protein extraction and western blot analysis. 1 × 106 cells were collected by
centrifugation, washed twice with cold PBS and resuspended in 100 μl of 1× Laemmli
Sample buffer (Bio-Rad) with freshly added β-mercaptoethanol (Sigma-Aldrich). The
supernatant was collected by centrifugation and boiled for 5min. Fifteen microliters
of the resulting protein lysate was separated by 4–12% SDS-PAGE.
For BIN1 detection, 2.5×106 cells were washed twice with cold PBS, lysed on ice
for 10 min with hypotonic buffer (20 mM HEPES (2-[4-(2-hydroxyethyl)piperazin-
1-yl]ethanesulfonic acid) pH 8.0, 10 mM KCl, 1 mM MgCl2, 20% glycerol, and
0.1% Triton-X100) and cleared by centrifugation. The pellets were resuspended in
high salt lysis buffer (10 mM Tris-HCl, PH7.9, 420 mM NaCl and 0.1% NP-40),
and then sonicated ﬁve cycles (15 s on/10 s off) in a Bioruptor (Diagenode). The
supernatant nuclear fraction was collected after centrifugation. Protein
concentration was measured by Spectrophotometer DS-11 FX (DeNovix) and the
protein lysate was separated on 4–12% SDS-PAGE gels.
Protein was transferred to polyvinylidene diﬂuoride membranes, which were
blocked in 5% skim milk in tris-buffered saline supplemented with 0.05% Tween 20
and incubated with primary antibodies overnight at 4 °C and hereafter with
horseradish peroxidase (HRP)-conjugated secondary antibody (1:4000, Dako),
diluted in tris-buffered saline-0.05%Tween20, for 1 h at room temperature.
Proteins were detected by enhanced chemiluminescence (Thermo Fisher
Scientiﬁc). The following antibodies were used: anti-RBM25 (sc-374271, Santa
Cruz Biotechnology, 1:1000 dilution), anti-BIN1 (ab182562, Abcam, 1:1000
dilution), anti-c-MYC (sc-40, Santa Cruz Biotechnology, 1:1000 dilution), anti-H3
(ab10799, Abcam) and anti-β-actin (A3854, Sigma-Aldrich). Uncropped scans of
all shown western blots are available in Supplementary Fig. 7.
Transient transfections/dual luciferase assay. Cells were grown to conﬂuence
in six-well plates and transfected with 1 μg of pBV-WT or pBV-MUT (Addgene)
and 1 μg of the control pRL-SV40 vector (Promega) using TransIT®-Jurkat
Transfection Reagent (MIRUS) according to the manufacturer’s recommendations.
Twenty-four hours posttransfection, the cells were lysed and assayed using the dual
luciferase reporter assay system (Promega) on a Glomax 96 instrument (Promega).
RNA immunoprecipitation. 1 × 106 cells were pelleted by centrifugation at 300 × g
for 10 min at 4 °C and washed twice with ice-cold PBS. Cell pellets were resus-
pended in 100 μl of polysome lysis buffer (100 mM KCl, 5 mM MgCl2,10 mM
HEPES pH 7.0, and 0.5% NP40) supplemented with 1 mM DL-Dithiothreitol,
protease inhibitor cocktail (Sigma-Aldrich) and Ribonuclease inhibitor (Sigma-
Aldrich), incubated on ice for 5 min and pelleted at 15,000 × g for 15 min. The
cleared supernatant was incubated with anti-RBM25-coated protein-A agarose
beads (Sigma-Aldrich) for 4 h at 4 °C and then washed four times with ice-cold
washing buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM MgCl2, and 0.05%
NP40). The beads were resuspended in 100 μl washing buffer supplemented with
proteinase K and incubated at 55 °C for 30 min to release the RNA-protein com-
ponents. The RNA was isolated using Trizol (Invitrogen) and subsequently reverse-
transcribed using the ProtoScript cDNA synthesis kit (New England Biolabs).
RNA-Seq analysis. RNA was extracted from 1×106 cells using the AllPrep DNA/
RNA Mini kit (Qiagen) according to the manufacturer’s recommendations. For
RNA-seq library generation, 1 μg RNA was fragmented, size selected (350–500 bp),
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reverse-transcribed according to the TruSeq RNA Library Prep Kit V2 sample
preparation guide (Illumina). The libraries were analyzed by Qbit and Agilent
Bioanalyzer High sensitivity assay (Agilent) and pooled in equimolar amounts.
Multiplexed samples were sequenced on an Illumina HiSeq 2500 system at the
Danish National High-Throughput DNA Sequencing Centre, University of
Copenhagen (Copenhagen, Denmark). Each sample yielded 80–100 million 100-
nucleotide paired-end reads.
For differential gene expression analysis, reads were mapped to human genome
(hg19) using STAR (default parameters)51. Expression levels for GENCODE gene
annotations (v19) were quantiﬁed using featureCounts52. Differential gene
expression analysis between shRBM25 and shScr was performed using DESeq252 at
an false discovery rate of <0.05.
Gene set enrichment analysis (GSEA; http://www.broadinstitute.org/gsea/index.jsp)
was performed on shRBM25 vs. shScr triplicate expression ﬁles. For all gene sets, 1000
permutations and the Signal2Noise metric were used. Permutations by gene sets were
conducted to assess statistical signiﬁcance.
For the analysis of alternative splicing we used a computational pipeline
involving the following steps: (a) Mapping of RNA-seq data to human genome
(hg19) using TopHat v. 2.0.1353, (b) Transcript quantiﬁcation using Cufﬂinks v.
2.2.154. (c) The resulting full-length transcripts were annotated with classes of
alternative splicing using the Bioconductor package spliceR26 with default settings.
Additional bioinformatics analysis. For TCGA AML data analysis, RNA-Seq data
and survival data of AML patients of all cytogenetic risk groups were downloaded
from the TCGA AML data portal55. BCL2L1-L expression was calculated as Log2
expression of the sum of Ensemble transcript IDs ENST00000307677 and
ENST00000376062. BCL2L1-S expression was calculated as the expression of
Ensemble transcript ID ENST00000376055. BIN1(+12) expression was calculated
as the sum of the expression of exon 12-including Ensemble transcripts
(ENST00000259238, ENST00000316724, ENST00000346226, ENST00000393040,
ENST00000484253).
For the assessment of the correlation between RBM25 levels and MYC target
gene expression in patient samples, gene signatures from the MSigDB database
were used to score patients from the TCGA cohort. Brieﬂy, for each signature
related to MYC, we computed the average of the log2-transformed gene expression
values, using the expression of all genes in the signature normalized to the level of
MYC expression. MYC normalization was performed in order to remove
confounding differences in MYC expression levels. The TCGA patient cohort was
then divided in two, based on the expression levels of RBM25 in each patient, and
gene signature scores compared between groups (Mann−Whitney U test).
Statistics and general methods. Sample sizes were not predetermined but are
indicated in relevant ﬁgures. No blinding of experimental groups was performed.
The number of times an experiment was performed is indicated in the ﬁgure
legends. All statistical analyses were performed using Prism version 7.0 software
(GraphPad Software Inc.). Comparison between groups was performed by a two-
tailed, paired or unpaired Student’s t test. The log-rank test was used to assess
signiﬁcant differences between survival curves. A nonparametric Mann–Whitney
test was used for TCGA AML patient data analysis. Sample sizes chosen are
indicated in the individual ﬁgure legends. P < 0.05 was considered to be signiﬁcant.
The results were represented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 and
****P < 0.0001. Standard deviations are indicated on all ﬁgures.
Data availability
Sequencing data have been deposited to the Gene Expression Omnibus (GEO) with
the accession number GSE114027. Genome-wide transcriptome and mutational
proﬁles of human AML data were obtained from The Cancer Genome Atlas data
portal (http://www.cbioportal.org). The source data underlying Figs. 1a, c, 6a, b,
and Supplementary Figs 1c, 1d, 4a are provided as Supplementary Files. All other
data generated during this study are available from the authors on request.
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